Evidence map›Paper›PMID 34609453›Full record

ArticleJAMA2021

US Emergency Department Visits Attributed to Medication Harms, 2017-2019.

Daniel S Budnitz, Nadine Shehab, Maribeth C Lovegrove, Andrew I Geller, Jennifer N Lind, Daniel A Pollock

Open access · bronzeAbstract read
In one paragraph

Article in JAMA, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
94citing papers in PubMed, 4 pooled it
22.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

94 citing papers in PubMed, 4 syntheses or guidelines pooled it, 165 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. The first month after direct oral anticoagulants: a window of vulnerability.Research and practice in thrombosis and haemostasis · 2026
    Article
  14. Article
  15. Review
  16. Article
  17. Developing Longitudinal Post-Overdose Care: A Call to Action.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2026
    Article
  18. Article
  19. Navigating Medication Risk in the ED: Communication Preferences of Older Adults Regarding Deprescribing.Academic emergency medicine : official journal of the Society for Academic Emergency Medicine · 2026
    Article
  20. Anticoagulation Stewardship Program in the DOAC Era.Journal of clinical medicine · 2026
    Review

34 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Daniel S BudnitzDivision of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
Nadine ShehabDivision of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
Maribeth C LovegroveDivision of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
Andrew I GellerDivision of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
Jennifer N LindDivision of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
Daniel A PollockDivision of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
Centers for Disease Control and Prevention · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

importanceAssessing the scope of acute medication harms to patients should include both therapeutic and nontherapeutic medication use.

objectiveTo describe the characteristics of emergency department (ED) visits for acute harms from both therapeutic and nontherapeutic medication use in the US. DESIGN, SETTING, AND

participantsActive, nationally representative, public health surveillance based on patient visits to 60 EDs in the US participating in the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance Project from 2017 through 2019. EXPOSURES: Medications implicated in ED visits, with visits attributed to medication harms (adverse events) based on the clinicians' diagnoses and supporting data documented in the medical record. MAIN OUTCOMES AND MEASURES: Nationally weighted estimates of ED visits and subsequent hospitalizations for medication harms.

resultsBased on 96 925 cases (mean patient age, 49 years; 55% female), there were an estimated 6.1 (95% CI, 4.8-7.5) ED visits for medication harms per 1000 population annually and 38.6% (95% CI, 35.2%-41.9%) resulted in hospitalization. Population rates of ED visits for medication harms were higher for patients aged 65 years or older than for those younger than 65 years (12.1 vs 5.0 [95% CI, 7.4-16.8 vs 4.1-5.8] per 1000 population). Overall, an estimated 69.1% (95% CI, 63.6%-74.7%) of ED visits for medication harms involved therapeutic medication use, but among patients younger than 45 years, an estimated 52.5% (95% CI, 48.1%-56.8%) of visits for medication harms involved nontherapeutic use. The proportions of ED visits for medication harms involving therapeutic use were lowest for barbiturates (6.3%), benzodiazepines (11.1%), nonopioid analgesics (15.7%), and antihistamines (21.8%). By age group, the most frequent medication types and intents of use associated with ED visits for medication harms were therapeutic use of anticoagulants (4.5 [95% CI, 2.3-6.7] per 1000 population) and diabetes agents (1.8 [95% CI, 1.3-2.3] per 1000 population) for patients aged 65 years and older; therapeutic use of diabetes agents (0.8 [95% CI, 0.5-1.0] per 1000 population) for patients aged 45 to 64 years; nontherapeutic use of benzodiazepines (1.0 [95% CI, 0.7-1.3] per 1000 population) for patients aged 25 to 44 years; and unsupervised medication exposures (2.2 [95% CI, 1.8-2.7] per 1000 population) and therapeutic use of antibiotics (1.4 [95% CI, 1.0-1.8] per 1000 population) for children younger than 5 years. CONCLUSIONS AND RELEVANCE: According to data from 60 nationally representative US emergency departments, visits attributed to medication harms in 2017-2019 were frequent, with variation in products and intent of use by age.

Indexed as

Acute DiseaseAdolescentAdultAgedAge DistributionAge FactorsAnalgesics, Non-NarcoticAnti-Bacterial AgentsAnticoagulantsBarbituratesBenzodiazepinesChildChild, PreschoolConfidence IntervalsDrug-Related Side Effects and Adverse ReactionsEmergency Service, HospitalAnalgesics, Non-NarcoticAnti-Bacterial AgentsAnticoagulantsBarbituratesBenzodiazepinesHistamine AntagonistsHypoglycemic AgentsNonprescription Drugs

Identifiers

PMID34609453
PMCPMC8493432
OpenAlexW3202203528

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.